Publication Results (31)

• Adherence to osteoporosis pharmacotherapy is underestimated using days supply values in electronic pharmacy claims data

  Burden AM, Paterson JM, Gruneir A, Cadarette SM. Pharmacoepidemiol Drug Saf. 2015; 24(1):67-74. Epub 2014 Oct 21.

• Trends in heart failure outcomes and pharmacotherapy: 1992 to 2000

  Lee DS, Mamdani MM, Austin PC, Gong Y, Liu PP, Rouleau JL, Tu JV. Am J Med. 2004; 116(9):581-9.

• Trends in selection and timing of first-line pharmacotherapy in older patients with Type 2 diabetes diagnosed between 1994 and 2006

  Foster PD, Mamdani MM, Juurlink DN, Shah BR, Paterson JM, Gomes T. Diabet Med. 2013; 30(10):1209-13. Epub 2013 Apr 16.

• Risk-treatment mismatch in the pharmacotherapy of heart failure

  Lee DS, Tu JV, Juurlink DN, Alter DA, Ko DT, Austin PC, Chong A, Stukel TA, Levy D, Laupacis A. JAMA. 2005; 294(10):1240-7.

• Resident-level predictors of dementia pharmacotherapy at long-term care admission: the impact of different drug reimbursement policies in Ontario and Saskatchewan

  Maclagan LC, Bronskill SE, Campitelli MA, Yao S5, Dharma C, Hogan DB, Herrmann N, Amuah JE, Maxwell CJ. Can J Psychiatry. 2020; 65(11):790-801. Epub 2020 Apr 10. DOI: https://doi.org/10.1177/0706743720909293

• Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction

  Rasmussen JN, Chong A, Alter DA. JAMA. 2007; 297(2):177-86.

• Osteoporosis quality indicators using healthcare utilization data

  Cadarette SM, Jaglal SB, Raman-Wilms L, Beaton DE, Paterson JM. Osteoporos Int. 2011; 22(5):1335-42. Epub 2010 Jun 25.

• Subgroups, treatment effects, and baseline risks: some lessons from major cardiovascular trials

  Parker AB, Naylor CD. Am Heart J. 2000; 139(6):952-61.

• Osteoporosis management and fractures in the Métis of Ontario, Canada

  Jandoc R, Jembere N, Khan S, Russell SJ, Allard Y, Cadarette SM. Arch Osteoporos. Epub 2015 Apr 25.

• Effectiveness of community-wide and individual high-risk strategies to prevent diabetes: a modelling study

  Manuel DG, Rosella LC, Tuna M, Bennett C, Stukel TA. PLoS One. 2013; 8(1):e52963. Epub 2013 Jan 4.

• Relationship between cardiac rehabilitation and survival after acute cardiac hospitalization within a universal health care system

  Alter DA, Oh PI, Chong A. Eur J Cardiovasc Prev Rehabil. 2009; 16(1):102-13.

• Medical comorbidity, acute medical care use in late-life bipolar disorder: a comparison of lithium, valproate, and other pharmacotherapies

  Rej S, Yu C, Shulman K, Herrmann N, Fischer HD, Fung K, Gruneir A. Gen Hosp Psychiatry. 2015; 37(6):528-32. Epub 2015 Jul 11.

• Screening and treatment for osteoporosis after stroke: results from the Ontario stroke registry

  Kapoor E, Austin PC, Alibhai SMH, Cheung AM, Cram P, Casaubon LK, Fang J, Porter J, Smith EE, Prager M, Kapral MK. Stroke. 2019; 50(6):1564-6. Epub 2019 Apr 25. DOI: 10.1161/STROKEAHA.118.024685.

• Impact of policy changes and drug shortages on acamprosate and naltrexone use in Ontario, Canada

  Konstantelos N, Tourchian N, McCormack D, Lecce P, Tadrous M, Gomes T. Drug Alcohol Depend. 2022; Nov 19 [Epub ahead of print]. DOI: https://doi.org/10.1016/j.drugalcdep.2022.109705

• Warfarin therapy and risk of hip fracture among elderly patients

  Mamdani M, Upshur RE, Anderson G, Bartle B, Laupacis A. Pharmacotherapy. 2003; 23(1):1-4.

• The challenges of prescribing drug therapy to older people

  Dergal J, Rochon P. Geriatr Aging. 2001; 4(1):7-8.

• Universal drug coverage and socioeconomic disparities in major diabetes outcomes

  Booth GL, Bishara P, Lipscombe LL, Shah BR, Feig DS, Bhattacharyya O, Bierman AS. Diabetes Care. 2012; 35(11):2257-64. Epub 2012 Aug 13.

• Secondary prevention treatment after acute stroke in older South Asian, Chinese and other Canadians: a retrospective data analysis

  Khan NA, McAlister FA, Pilote L, Palepu A, Quan H, Hill MD, Fang J, Kapral MK. CMAJ Open. 2017; 5(3):E702-9.

• Examining exposure misclassification of oral bisphosphonate therapy and the associated fracture risk: a cohort study

  Burden AM, Gruneir A, Paterson JM, Cadarette SM. Adv Pharmacoepidemiol Drug Saf. 2015; 4:4.

• Thromboembolic prophylaxis in moderate-risk patients undergoing elective abdominal surgery: decision and cost-effectiveness analyses

  Mamdani MM, Weingarten CM, Stevenson JG. Pharmacotherapy. 1996;16(6):1111-27.

• CCORT/CCS quality indicators for congestive heart failure care

  Lee DS, Tran C, Flintoft V, Grant FC, Liu PP, Tu JV; Canadian Cardiovascular Outcomes Research Team/Canadian Cardiovascular Society Heart Failure Quality Indicator Panel. Can J Cardiol. 2003; 19(4):357-64.

• Investigating the determinants of decreasing postmyocardial infarction mortality: an analysis of in-hospital data from 1992 and 1997

  Daneman N, Austin PC, Tu JV. Can J Cardiol. 2001; 17(7):771-6.

• The risk of postpartum hemorrhage with selective serotonin reuptake inhibitors and other antidepressants

  Salkeld E, Ferris LE, Juurlink DN. J Clin Psychopharm. 2008; 28(2):230-4.

• From pharmaco-therapy to pharmaco-prevention: trends in prescribing to older adults in Ontario, Canada, 1997-2006

  Bajcar JM, Wang L, Moineddin R, Nie JX, Tracy CS, Upshur RE. BMC Fam Pract. 2010; 11:75.

• Impact of the JUPITER trial on statin prescribing for primary prevention

  Teng JF, Gomes T, Camacho X, Grundy S, Juurlink DN, Mamdani MM. Pharmacotherapy. 2014; 34(1):9-18. Epub 2013 Aug 12.

• Modelling preventive effectiveness to estimate the equity tipping point: at what coverage can individual preventive interventions reduce socioeconomic disparities in diabetes risk?

  Manuel DG, Ho TH, Harper S, Anderson GM, Lynch J, Rosella LC. Chronic Dis Inj Can. 2014; 34(2-3):94-102.

• Varenicline and risk of self-harm: a nested case-control study

  Tadrous M, Martins D, Yao Z, Mamdani MM, Juurlink DN, Gomes T, Antoniou T. PLoS One. 2016; 11(9):e0163681.

• Angiotensin receptor blockers vs. angiotensin converting enzyme inhibitors and acute coronary syndrome outcomes in elderly patients: a population-based cohort study (UMPIRE study results)

  Verma S, Mamdani MM, Al-Omran M, Melo M, Rouleau JL. J Am Soc Hypertens. 2007; 1(4):286-94.

• Renin-angiotensin-aldosterone system inhibitors and major cardiovascular events and acute kidney injury in patients with coronary artery disease

  Sud M, Ko DT, Chong A, Koh M, Azizi P, Austin PC, Stukel T, Jackevicius CA. Pharmacotherapy. 2021; 41(12):988-97. Epub 2021 Sep 8. DOI: https://doi.org/10.1002/phar.2624

• Association between concurrent use of amiodarone and DOACs and risk of bleeding in patients with atrial fibrillation

  Shurrab M, Jackevicius CA, Austin PC, Tu K, Qiu F, Singh SM, Crystal E, Caswell J, Michael F, Andrade JG, Ko DT. Am J Cardiol. 2022; Nov 4 [Epub ahead of print]. DOI: https://doi.org/10.1016/j.amjcard.2022.10.031

• Comparison of medication prescribing before and after the COVID-19 pandemic among nursing home residents in Ontario, Canada

  Campitelli MA, Bronskill SE, Maclagan LC, Harris DA, Cotton CA, Tadrous M, Gruneir A, Hogan DB, Maxwell CJ. JAMA Netw Open. 2021; 4(8):e2118441. Epub 2021 Aug 2. DOI: https://doi.org/10.1001/jamanetworkopen.2021.18441